The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc’s cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/qveeMZpPUC8/fda-approves-expanded-label-for-regeneron-sanofis-cholesterol-drug-idINKCN1S301W
